The US Food and Drug Administration (FDA) and drugmaker Pharmacia are advising doctors that the firm’s COX-2 inhibitor valdecoxib (Bextra) has been associated with serious allergic reactions and should not be prescribed to patients allergic to sulfa.
In a notice issued on Friday, the FDA said it has received post-marketing reports regarding various allergic events, including skin and anaphylactoid reactions. Although the events were rare, some patients required hospitalization, the FDA added.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!